After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi
pharmaphorum
JUNE 3, 2021
The US regulator approved Lybalvi (olanzapine/samidorphan) for both indications sought – schizophrenia and bipolar I disorder – with data on its label that includes a claim of less weight gain with olanzapine on its own, a big problem with the widely-used generic drug that affects compliance with treatment.
Let's personalize your content